

Rozenman Mary M.
Form 4
December 28, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Rozenman Mary M.

2. Issuer Name and Ticker or Trading Symbol
Aimmune Therapeutics, Inc. [AIMT]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

(Last) (First) (Middle)
AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
12/26/2017

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
See Remarks

BRISBANE, CA 94005-1884

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.0001 par value	12/26/2017		M	75,010 A	\$ 3.022 75,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾	11,000 D	\$ 38.8263 64,139	D	
Common Stock, \$0.0001	12/26/2017		S ⁽¹⁾	1,500 D	\$ 39.252 62,639	D	

Edgar Filing: Rozenman Mary M. - Form 4

par value							
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	10,700	D	\$ 38.8151 <u>(2)</u>	51,939	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	1,800	D	\$ 39.225 <u>(4)</u>	50,139	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	11,000	D	\$ 38.8286 <u>(5)</u>	39,139	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	1,500	D	\$ 39.25 <u>(6)</u>	37,639	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	11,000	D	\$ 38.8221 <u>(7)</u>	26,639	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	1,500	D	\$ 39.2313 <u>(8)</u>	25,139	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	4,310	D	\$ 38.8026 <u>(9)</u>	20,829	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	700	D	\$ 39.2557 <u>(10)</u>	20,129	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	8,800	D	\$ 38.8253 <u>(11)</u>	11,329	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	1,200	D	\$ 39.2783 <u>(12)</u>	10,129	D
Common Stock, \$0.0001 par value	12/26/2017	<u>S⁽¹⁾</u>	6,400	D	\$ 38.7263 <u>(13)</u>	3,729	D

Edgar Filing: Rozenman Mary M. - Form 4

- (1) The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from \$38.13 to \$39.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (2) The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (3) The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (4) The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (5) The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (6) The transaction was executed in multiple trades in prices ranging from \$38.12 to \$39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (7) The transaction was executed in multiple trades in prices ranging from \$39.13 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (8) The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (9) The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (10) The transaction was executed in multiple trades in prices ranging from \$38.15 to \$39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (11) The transaction was executed in multiple trades in prices ranging from \$39.16 to \$39.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (12) The transaction was executed in multiple trades in prices ranging from \$38.06 to \$39.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (13) The transaction was executed in multiple trades in prices ranging from \$39.07 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- (14) The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- (15)

Remarks:

Senior VP, Corporate Development and Strategy

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.